Cellebrite filed an initial statement of beneficial ownership reporting holdings by Armon Ronnen, Chief Products and Technologies Officer. Ronnen reported direct beneficial ownership of 277,844 ordinary shares. He also reported stock options covering 60,606 ordinary shares with an exercise price of USD 6.6. He reported additional stock options covering 80,808 ordinary shares with an exercise price of USD 4.95. He reported two more stock option positions, each covering 43,440 ordinary shares with an exercise price of USD 11.51.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cellebrite DI Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-029855), on March 18, 2026, and is solely responsible for the information contained therein.
Comments